Drug profile

The FDA adverse-event record for Enrofloxacin + Ketoconazole + Triamcinolone + Silver Sulfadazine + Tobramycin + Polymixin B

14 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Enrofloxacin + Ketoconazole + Triamcinolone + Silver Sulfadazine + Tobramycin + Polymixin B. See the species affected, top reactions, and outcomes below.

14
adverse-event reports
0.0%
death-coded share
Dog
most-reported species
4
Lack of efficacy - NOS - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
14
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Enrofloxacin + Ketoconazole + Triamcinolone + Silver Sulfadazine + Tobramycin + Polymixin B

Administration Routes

Auricular (Otic)Unknown

Species Affected

Dog 13
Cat 1

Most Affected Breeds

Retriever - Labrador 3
Spaniel - Cocker American 2
Retriever - Golden 1
Rottweiler 1
Schnauzer (unspecified) 1
Spitz - German Pomeranian 1
Chihuahua 1
Domestic Shorthair 1
Bulldog 1
Hound - Basset 1

Most Reported Reactions

Lack of efficacy - NOS 4
Emesis 3
Weight loss 3
Vomiting 3
INEFFECTIVE, HEARTWORM LARVAE 2
Leucocytosis NOS 2
Not eating 2
Immune mediated haemolytic anaemia 2
Splenomegaly 2
Elevated serum alkaline phosphatase (SAP) 2
Decreased activity 2
Otitis externa 2

Outcome Breakdown

Outcome Unknown
6 (42.9%)
Ongoing
5 (35.7%)
Recovered/Normal
3 (21.4%)

Enrofloxacin + Ketoconazole + Triamcinolone + Silver Sulfadazine + Tobramycin + Polymixin B Adverse Event Insights

14 reports name Enrofloxacin + Ketoconazole + Triamcinolone + Silver Sulfadazine + Tobramycin + Polymixin B; 0 recorded a death outcome (0.0% of reported events, not a population-level mortality rate). Active ingredient: Enrofloxacin + Ketoconazole + Triamcinolone + Silver Sulfadazine + Tobramycin + Polymixin B. Administration routes: Auricular (Otic), Unknown.

By species: Dog (13 reports), Cat (1 reports). By breed: Retriever - Labrador (3), Spaniel - Cocker American (2), Retriever - Golden (1).

Leading clinical signs: Lack of efficacy - NOS (4), Emesis (3), Weight loss (3), Vomiting (3). Outcome, 14 coded reports: Outcome Unknown leads at 42.9%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.